Retiming the failing heart: principles and current clinical status of cardiac resynchronization

Left or biventricular (BiV) pacing, or cardiac resynchronization therapy, was proposed nearly 10 years ago as an adjunctive treatment for patients with advanced heart failure (HF) complicated by discoordinate contraction due to intraventricular conduction delay. Since then, both short-term and a gro...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology 2002-01, Vol.39 (2), p.194-201
Main Authors: Leclercq, Christophe, Kass, David A.
Format: Article
Language:English
Subjects:
Biological and medical sciences
Cardiac arrhythmia
Cardiac Pacing, Artificial - methods
Cardiology
Clinical Trials as Topic
Defibrillators, Implantable
Electrocardiography
Heart
Heart Failure - physiopathology
Heart Failure - therapy
Humans
Medical sciences
Mortality
Principles
Quality of life
Treatment Outcome
Ventricular Dysfunction, Left - physiopathology
Ventricular Dysfunction, Left - therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c453t-66dc436b02422e415961a6649f7fbd58e2faf9f6c005c8742a2d3b2b7bc00ab83
cites cdi_FETCH-LOGICAL-c453t-66dc436b02422e415961a6649f7fbd58e2faf9f6c005c8742a2d3b2b7bc00ab83
container_end_page 201
container_issue 2
container_start_page 194
container_title Journal of the American College of Cardiology
container_volume 39
creator Leclercq, Christophe
Kass, David A.
description Left or biventricular (BiV) pacing, or cardiac resynchronization therapy, was proposed nearly 10 years ago as an adjunctive treatment for patients with advanced heart failure (HF) complicated by discoordinate contraction due to intraventricular conduction delay. Since then, both short-term and a growing number of long-term clinical trials have reported on the mechanisms and short- and mid-term efficacy of this approach, with encouraging results. Therapy is implemented with novel pacing systems incorporating an endocardial lead to stimulate the lateral free wall via a cardiac vein, and often a right ventricular (RV) apex lead to provide BiV stimulation. A third atrial sensing lead monitors intrinsic rhythm and provides timing data to ensure ventricular pre-excitation. Modulation of the electronic atrial-ventricular (AV) time delay can optimize contractile synchrony, enhance the contribution of atrial systole, and reduce mitral regurgitation. Individuals with advanced HF, a wide QRS complex often with an AV time delay, and evidence of contraction dyssynchrony in viable myocardium represent the target patient group. Short-term studies reveal systolic augmentation and chamber efficiency from pacing resynchronization that can be substantial. Long-term studies reveal improved symptoms and exercise capacity, and some report reversal of chronic cardiac dilation. However, important questions regarding long-term efficacy and mortality impact, optimal mode for pacing stimulation, and role of combined pacing/cardioverter/defibrillation devices remain unresolved. Here we review pathophysiologic mechanisms, short- and long-term clinical results, and future directions of this new and promising therapy.
doi_str_mv 10.1016/S0735-1097(01)01747-8
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71369850</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0735109701017478</els_id><sourcerecordid>3242294001</sourcerecordid><originalsourceid>FETCH-LOGICAL-c453t-66dc436b02422e415961a6649f7fbd58e2faf9f6c005c8742a2d3b2b7bc00ab83</originalsourceid><addsrcrecordid>eNqF0F1rFDEUgOEgit1Wf4ISEItejJ7M5Gu8ESlqCwXBj-uQyZy4KbOZbZIp1F9vtru04I1XCeHJ4fAS8oLBOwZMvv8BqhMNg169AfYWmOKq0Y_Iigmhm0706jFZ3ZMjcpzzFQBIzfqn5IgxpXULakXMdyxhE-JvWtZIvQ3T7r5Gm8oHuk0hurCdMFMbR-qWlDAW6qoJzk40F1uWTGdPnU1jsI4mzLfRrdMcwx9bwhyfkSfeThmfH84T8uvL559n583lt68XZ58uG8dFVxopR8c7OUDL2xY5E71kVkree-WHUWhsvfW9lw5AOK14a9uxG9pBDfXFDro7Iaf7uds0Xy-Yi9mE7HCabMR5yUaxTvZaQIWv_oFX85Ji3c0wARJ6LpmqSuyVS3POCb2pLTY23RoGZtff3PU3u7gGmLnrb3ZrvDxMX4YNjg-_DsEreH0ANteEPtlaOD-4jnOpe1bdx73DGu0mYDLZBYwOx5DQFTPO4T-r_AXt4KIu</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1506094617</pqid></control><display><type>article</type><title>Retiming the failing heart: principles and current clinical status of cardiac resynchronization</title><source>BACON - Elsevier - GLOBAL_SCIENCEDIRECT-OPENACCESS</source><creator>Leclercq, Christophe ; Kass, David A.</creator><creatorcontrib>Leclercq, Christophe ; Kass, David A.</creatorcontrib><description>Left or biventricular (BiV) pacing, or cardiac resynchronization therapy, was proposed nearly 10 years ago as an adjunctive treatment for patients with advanced heart failure (HF) complicated by discoordinate contraction due to intraventricular conduction delay. Since then, both short-term and a growing number of long-term clinical trials have reported on the mechanisms and short- and mid-term efficacy of this approach, with encouraging results. Therapy is implemented with novel pacing systems incorporating an endocardial lead to stimulate the lateral free wall via a cardiac vein, and often a right ventricular (RV) apex lead to provide BiV stimulation. A third atrial sensing lead monitors intrinsic rhythm and provides timing data to ensure ventricular pre-excitation. Modulation of the electronic atrial-ventricular (AV) time delay can optimize contractile synchrony, enhance the contribution of atrial systole, and reduce mitral regurgitation. Individuals with advanced HF, a wide QRS complex often with an AV time delay, and evidence of contraction dyssynchrony in viable myocardium represent the target patient group. Short-term studies reveal systolic augmentation and chamber efficiency from pacing resynchronization that can be substantial. Long-term studies reveal improved symptoms and exercise capacity, and some report reversal of chronic cardiac dilation. However, important questions regarding long-term efficacy and mortality impact, optimal mode for pacing stimulation, and role of combined pacing/cardioverter/defibrillation devices remain unresolved. Here we review pathophysiologic mechanisms, short- and long-term clinical results, and future directions of this new and promising therapy.</description><identifier>ISSN: 0735-1097</identifier><identifier>EISSN: 1558-3597</identifier><identifier>DOI: 10.1016/S0735-1097(01)01747-8</identifier><identifier>PMID: 11788207</identifier><identifier>CODEN: JACCDI</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Biological and medical sciences ; Cardiac arrhythmia ; Cardiac Pacing, Artificial - methods ; Cardiology ; Clinical Trials as Topic ; Defibrillators, Implantable ; Electrocardiography ; Heart ; Heart Failure - physiopathology ; Heart Failure - therapy ; Humans ; Medical sciences ; Mortality ; Principles ; Quality of life ; Treatment Outcome ; Ventricular Dysfunction, Left - physiopathology ; Ventricular Dysfunction, Left - therapy</subject><ispartof>Journal of the American College of Cardiology, 2002-01, Vol.39 (2), p.194-201</ispartof><rights>2002 American College of Cardiology</rights><rights>2002 INIST-CNRS</rights><rights>Copyright Elsevier Limited Jan 16, 2002</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c453t-66dc436b02422e415961a6649f7fbd58e2faf9f6c005c8742a2d3b2b7bc00ab83</citedby><cites>FETCH-LOGICAL-c453t-66dc436b02422e415961a6649f7fbd58e2faf9f6c005c8742a2d3b2b7bc00ab83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=13446891$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11788207$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Leclercq, Christophe</creatorcontrib><creatorcontrib>Kass, David A.</creatorcontrib><title>Retiming the failing heart: principles and current clinical status of cardiac resynchronization</title><title>Journal of the American College of Cardiology</title><addtitle>J Am Coll Cardiol</addtitle><description>Left or biventricular (BiV) pacing, or cardiac resynchronization therapy, was proposed nearly 10 years ago as an adjunctive treatment for patients with advanced heart failure (HF) complicated by discoordinate contraction due to intraventricular conduction delay. Since then, both short-term and a growing number of long-term clinical trials have reported on the mechanisms and short- and mid-term efficacy of this approach, with encouraging results. Therapy is implemented with novel pacing systems incorporating an endocardial lead to stimulate the lateral free wall via a cardiac vein, and often a right ventricular (RV) apex lead to provide BiV stimulation. A third atrial sensing lead monitors intrinsic rhythm and provides timing data to ensure ventricular pre-excitation. Modulation of the electronic atrial-ventricular (AV) time delay can optimize contractile synchrony, enhance the contribution of atrial systole, and reduce mitral regurgitation. Individuals with advanced HF, a wide QRS complex often with an AV time delay, and evidence of contraction dyssynchrony in viable myocardium represent the target patient group. Short-term studies reveal systolic augmentation and chamber efficiency from pacing resynchronization that can be substantial. Long-term studies reveal improved symptoms and exercise capacity, and some report reversal of chronic cardiac dilation. However, important questions regarding long-term efficacy and mortality impact, optimal mode for pacing stimulation, and role of combined pacing/cardioverter/defibrillation devices remain unresolved. Here we review pathophysiologic mechanisms, short- and long-term clinical results, and future directions of this new and promising therapy.</description><subject>Biological and medical sciences</subject><subject>Cardiac arrhythmia</subject><subject>Cardiac Pacing, Artificial - methods</subject><subject>Cardiology</subject><subject>Clinical Trials as Topic</subject><subject>Defibrillators, Implantable</subject><subject>Electrocardiography</subject><subject>Heart</subject><subject>Heart Failure - physiopathology</subject><subject>Heart Failure - therapy</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Mortality</subject><subject>Principles</subject><subject>Quality of life</subject><subject>Treatment Outcome</subject><subject>Ventricular Dysfunction, Left - physiopathology</subject><subject>Ventricular Dysfunction, Left - therapy</subject><issn>0735-1097</issn><issn>1558-3597</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><recordid>eNqF0F1rFDEUgOEgit1Wf4ISEItejJ7M5Gu8ESlqCwXBj-uQyZy4KbOZbZIp1F9vtru04I1XCeHJ4fAS8oLBOwZMvv8BqhMNg169AfYWmOKq0Y_Iigmhm0706jFZ3ZMjcpzzFQBIzfqn5IgxpXULakXMdyxhE-JvWtZIvQ3T7r5Gm8oHuk0hurCdMFMbR-qWlDAW6qoJzk40F1uWTGdPnU1jsI4mzLfRrdMcwx9bwhyfkSfeThmfH84T8uvL559n583lt68XZ58uG8dFVxopR8c7OUDL2xY5E71kVkree-WHUWhsvfW9lw5AOK14a9uxG9pBDfXFDro7Iaf7uds0Xy-Yi9mE7HCabMR5yUaxTvZaQIWv_oFX85Ji3c0wARJ6LpmqSuyVS3POCb2pLTY23RoGZtff3PU3u7gGmLnrb3ZrvDxMX4YNjg-_DsEreH0ANteEPtlaOD-4jnOpe1bdx73DGu0mYDLZBYwOx5DQFTPO4T-r_AXt4KIu</recordid><startdate>20020116</startdate><enddate>20020116</enddate><creator>Leclercq, Christophe</creator><creator>Kass, David A.</creator><general>Elsevier Inc</general><general>Elsevier Science</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20020116</creationdate><title>Retiming the failing heart: principles and current clinical status of cardiac resynchronization</title><author>Leclercq, Christophe ; Kass, David A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c453t-66dc436b02422e415961a6649f7fbd58e2faf9f6c005c8742a2d3b2b7bc00ab83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Biological and medical sciences</topic><topic>Cardiac arrhythmia</topic><topic>Cardiac Pacing, Artificial - methods</topic><topic>Cardiology</topic><topic>Clinical Trials as Topic</topic><topic>Defibrillators, Implantable</topic><topic>Electrocardiography</topic><topic>Heart</topic><topic>Heart Failure - physiopathology</topic><topic>Heart Failure - therapy</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Mortality</topic><topic>Principles</topic><topic>Quality of life</topic><topic>Treatment Outcome</topic><topic>Ventricular Dysfunction, Left - physiopathology</topic><topic>Ventricular Dysfunction, Left - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Leclercq, Christophe</creatorcontrib><creatorcontrib>Kass, David A.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the American College of Cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Leclercq, Christophe</au><au>Kass, David A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Retiming the failing heart: principles and current clinical status of cardiac resynchronization</atitle><jtitle>Journal of the American College of Cardiology</jtitle><addtitle>J Am Coll Cardiol</addtitle><date>2002-01-16</date><risdate>2002</risdate><volume>39</volume><issue>2</issue><spage>194</spage><epage>201</epage><pages>194-201</pages><issn>0735-1097</issn><eissn>1558-3597</eissn><coden>JACCDI</coden><notes>ObjectType-Article-2</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-3</notes><notes>content type line 23</notes><notes>ObjectType-Review-1</notes><abstract>Left or biventricular (BiV) pacing, or cardiac resynchronization therapy, was proposed nearly 10 years ago as an adjunctive treatment for patients with advanced heart failure (HF) complicated by discoordinate contraction due to intraventricular conduction delay. Since then, both short-term and a growing number of long-term clinical trials have reported on the mechanisms and short- and mid-term efficacy of this approach, with encouraging results. Therapy is implemented with novel pacing systems incorporating an endocardial lead to stimulate the lateral free wall via a cardiac vein, and often a right ventricular (RV) apex lead to provide BiV stimulation. A third atrial sensing lead monitors intrinsic rhythm and provides timing data to ensure ventricular pre-excitation. Modulation of the electronic atrial-ventricular (AV) time delay can optimize contractile synchrony, enhance the contribution of atrial systole, and reduce mitral regurgitation. Individuals with advanced HF, a wide QRS complex often with an AV time delay, and evidence of contraction dyssynchrony in viable myocardium represent the target patient group. Short-term studies reveal systolic augmentation and chamber efficiency from pacing resynchronization that can be substantial. Long-term studies reveal improved symptoms and exercise capacity, and some report reversal of chronic cardiac dilation. However, important questions regarding long-term efficacy and mortality impact, optimal mode for pacing stimulation, and role of combined pacing/cardioverter/defibrillation devices remain unresolved. Here we review pathophysiologic mechanisms, short- and long-term clinical results, and future directions of this new and promising therapy.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>11788207</pmid><doi>10.1016/S0735-1097(01)01747-8</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0735-1097
ispartof Journal of the American College of Cardiology, 2002-01, Vol.39 (2), p.194-201
issn 0735-1097
1558-3597
language eng
recordid cdi_proquest_miscellaneous_71369850
source BACON - Elsevier - GLOBAL_SCIENCEDIRECT-OPENACCESS
subjects Biological and medical sciences
Cardiac arrhythmia
Cardiac Pacing, Artificial - methods
Cardiology
Clinical Trials as Topic
Defibrillators, Implantable
Electrocardiography
Heart
Heart Failure - physiopathology
Heart Failure - therapy
Humans
Medical sciences
Mortality
Principles
Quality of life
Treatment Outcome
Ventricular Dysfunction, Left - physiopathology
Ventricular Dysfunction, Left - therapy
title Retiming the failing heart: principles and current clinical status of cardiac resynchronization
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T06%3A20%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Retiming%20the%20failing%20heart:%20principles%20and%20current%20clinical%20status%20of%20cardiac%20resynchronization&rft.jtitle=Journal%20of%20the%20American%20College%20of%20Cardiology&rft.au=Leclercq,%20Christophe&rft.date=2002-01-16&rft.volume=39&rft.issue=2&rft.spage=194&rft.epage=201&rft.pages=194-201&rft.issn=0735-1097&rft.eissn=1558-3597&rft.coden=JACCDI&rft_id=info:doi/10.1016/S0735-1097(01)01747-8&rft_dat=%3Cproquest_cross%3E3242294001%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c453t-66dc436b02422e415961a6649f7fbd58e2faf9f6c005c8742a2d3b2b7bc00ab83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1506094617&rft_id=info:pmid/11788207&rfr_iscdi=true